Lilly to Bring Rocketing Insulin Costs Down to Earth

US insulin manufacturer Eli Lilly has become the first to respond to the growing pressure from patients to cut the cost of insulin.

The company announced in March that it would offer a cheaper version of its top selling insulin Humalog in the USA. The decision follows a decision by Congress to investigate the three major insulin makers including Lilly.

Despite the political pressure, in January European drugmakers Sanofi and Novo Nordisk raised their prices for insulin in the US. The pressure is on all insulin producers to do Lilly to Bring Rocketing Insulin Costs Down to Earth more after months of rising prices forcing some patients to ration their dosages with reports of complications and even patient deaths.

The price rises in the US have been explained as a consequence of everyone taking a share in the price. It is less of an issue in public health care systems but they too are affected by price changes.

Advocacy Action: Your patient groups might welcome your support and your Government could be lobbied to put pressure on the producers and the supply chain.